Business
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic V...
Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S.
About this update from Dyadic International, Inc.
[{"type":"text","content":"Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases \n JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it has entered into a research collaboration agreement with the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital, as part of VIC’s collaboration with Voltron Therapeutics, Inc. (“Voltron”), to use Dyadic’s proprietary C1 protein production platform to express vaccine antigens for influenza A and other infectious diseases. This research collaboration resulted from a $5.88 million award that VIC received from the U.S. Department of Defense (“DoD”). The award is intended to be used to advance the development of a Self-Assembling Vaccine (“SAV”) Platform for rapid production of prophylactic vaccines for various infectious diseases. VIC will be working with Dyadic and Voltron with the goal of enabling the scalable, efficient, and rapid development of prophylactic vaccines applicable to various infectious diseases for use in the U.S. military, as well as in the general population. It is anticipated that the novel SAV platform will provide several unique features that offer a promising solution for the U.S. military’s needs, including speed of development, as well as targeting flexibility through the attachment of proteins, monoclonal antibodies, small molecules, neoantigens or lipids. SAVs have demonstrated the potential to cause more efficacious immune response and protection, which provides a promising strategy for vaccine construction. If successful, this collaboration represents a potential commercial opportunity for Dyadic to receive revenues from products brought to market through this and other projects. “I am excited to announce this collaboration with the VIC at Massachusetts General ...